Skip to main content
Premium Trial:

Request an Annual Quote

Sengenics Buys Oxford Gene Technology's Protein Array Platform

NEW YORK (GenomeWeb) – Sengenics today announced it has acquired Oxford Gene Technology's protein array technology for an undisclosed amount. 

The technology, which will be rebranded Immunome, is an auto-antibody profiling platform developed as a joint collaboration between the University o fOxford and the University of Cambridge. It is the only array platform in which every protein is full length, correctly folded, and functionally validated, Sengenics said, adding that Immunome ensures that only correctly folded proteins are presented on the array. 

The acquisition is anticipated to expand Sengenics' footprint in the proteomics space, it said. 

Applications for the technology include the monitoring of differential immune response to drugs and vaccines in clinical trials and the modeling of viral or bacterial infection. The platform can also be used as a biomarker discovery tool for immune system diseases such as cancer, neurodegenerative disorders, and autoimmune disorders. 

Sengenics said it will offer the technology as a product — in the form of protein microarray slides and associated reagents, and software — and as a service. Based in Brunei, Sengenics is a genomics- and proteomics-based research and diagnostics firm. 

The sale by OGT is its second announced in a week and follows the transfer of its next-generation sequencing services to Source Bioscience as the firm shifts its focus solely on its genomics products.